Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M L Salgaller

Showing results (21-30 of 37) with videos related to

Pageof 4
Sort By:
Cancer Research|March 8, 2000
Dendritic cell-based immunotherapy of prostate cancer: immune monitoring of a phase II clinical trialP A Lodge, L A Jones, R A Bader, et al.
International Immunology|May 18, 1999
Construction and binding analysis of recombinant single-chain TCR derived from tumor-infiltrating lymphocytes and a cytotoxic T lymphocyte clone directed against MAGE-1D F Lake, M L Salgaller, P van der Bruggen, et al.
Clinical & Experimental Metastasis|September 1, 1997
Expression of MAGE genes in ocular melanoma during progression from primary to metastatic diseaseP W Chen, T G Murray, T Uno, et al.
Current Eye Research|April 2, 1998
Uveal melanomas contain antigenically specific and non-specific infiltrating lymphocytesB R Ksander, D C Geer, P W Chen, et al.
Critical Reviews in Immunology|January 7, 1998
Dendritic cell-based immunotherapy of prostate cancerM L Salgaller, B A Tjoa, P A Lodge, et al.
American Journal of Obstetrics and Gynecology|December 1, 1996
Generation of tumor-specific cytolytic T lymphocytes from peripheral blood of cervical cancer patients by in vitro stimulation with a synthetic human papillomavirus type 16 E7 epitopeM Alexander, M L Salgaller, E Celis, et al.
Journal of Immunology (Baltimore, Md. : 1950)|September 15, 1996
Improved induction of melanoma-reactive CTL with peptides from the melanoma antigen gp100 modified at HLA-A*0201-binding residuesM R Parkhurst, M L Salgaller, S Southwood, et al.
The Cancer Journal From Scientific American|January 1, 1997
Enhancement of cellular immunity in melanoma patients immunized with a peptide from MART-1/Melan AJ N Cormier, M L Salgaller, T Prevette, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|July 15, 1999
Expression and purification of prostate-specific membrane antigen in the baculovirus expression system and recognition by prostate-specific membrane antigen-specific T cellsP A Lodge, R A Childs, S J Monahan, et al.
Journal of Immunology (Baltimore, Md. : 1950)|May 15, 1996
Binding and presentation of peptides derived from melanoma antigens MART-1 and glycoprotein-100 by HLA-A2 subtypes. Implications for peptide-based immunotherapyL Rivoltini, D J Loftus, K Barracchini, et al.
Pageof 4

Showing results (21-30 of 37) with videos related to

Sort By:
Pageof 4
Cancer Research|March 8, 2000
Dendritic cell-based immunotherapy of prostate cancer: immune monitoring of a phase II clinical trialP A Lodge, L A Jones, R A Bader, et al.
International Immunology|May 18, 1999
Construction and binding analysis of recombinant single-chain TCR derived from tumor-infiltrating lymphocytes and a cytotoxic T lymphocyte clone directed against MAGE-1D F Lake, M L Salgaller, P van der Bruggen, et al.
Clinical & Experimental Metastasis|September 1, 1997
Expression of MAGE genes in ocular melanoma during progression from primary to metastatic diseaseP W Chen, T G Murray, T Uno, et al.
Current Eye Research|April 2, 1998
Uveal melanomas contain antigenically specific and non-specific infiltrating lymphocytesB R Ksander, D C Geer, P W Chen, et al.
Critical Reviews in Immunology|January 7, 1998
Dendritic cell-based immunotherapy of prostate cancerM L Salgaller, B A Tjoa, P A Lodge, et al.
American Journal of Obstetrics and Gynecology|December 1, 1996
Generation of tumor-specific cytolytic T lymphocytes from peripheral blood of cervical cancer patients by in vitro stimulation with a synthetic human papillomavirus type 16 E7 epitopeM Alexander, M L Salgaller, E Celis, et al.
Journal of Immunology (Baltimore, Md. : 1950)|September 15, 1996
Improved induction of melanoma-reactive CTL with peptides from the melanoma antigen gp100 modified at HLA-A*0201-binding residuesM R Parkhurst, M L Salgaller, S Southwood, et al.
The Cancer Journal From Scientific American|January 1, 1997
Enhancement of cellular immunity in melanoma patients immunized with a peptide from MART-1/Melan AJ N Cormier, M L Salgaller, T Prevette, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|July 15, 1999
Expression and purification of prostate-specific membrane antigen in the baculovirus expression system and recognition by prostate-specific membrane antigen-specific T cellsP A Lodge, R A Childs, S J Monahan, et al.
Journal of Immunology (Baltimore, Md. : 1950)|May 15, 1996
Binding and presentation of peptides derived from melanoma antigens MART-1 and glycoprotein-100 by HLA-A2 subtypes. Implications for peptide-based immunotherapyL Rivoltini, D J Loftus, K Barracchini, et al.
Pageof 4